Individualized Treatment of Multidrug-resistant Tuberculosis Using Whole-Genome Sequencing and Expanded Drug-Susceptibility Testing-Reference-Cited by-同舟云学术

Individualized Treatment of Multidrug-resistant Tuberculosis Using Whole-Genome Sequencing and Expanded Drug-Susceptibility Testing

Published:2020-05-08 Issue:11 Volume:71 Page:2981-2985
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Dookie Navisha¹²,Padayatchi Nesri¹²,Lessells Richard J¹³,Naicker Cherise L¹²,Chotoo Sunitha⁴,Naidoo Kogieleum¹²

Affiliation:

1. Centre for the AIDS Programme of Research in South Africa (CAPRISA), Nelson R Mandela School of Medicine, College of Health Sciences, University of KwaZulu-Natal Durban, South Africa

2. South African Medical Research Council-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical Research Institute, University of KwaZulu-Natal Durban, South Africa

3. KwaZulu-Natal Research Innovation and Sequencing, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa

4. King Dinu-Zulu Hospital Complex, South African National Department of Health, eThekwini Health District, Durban, South Africa

Abstract

Abstract A case of multidrug-resistant tuberculosis is presented. It highlights the role of whole-genome sequencing, expanded phenotypic drug susceptibility testing, and enhanced case management, offering a more complete understanding of drug susceptibility to Mycobacterium tuberculosis. This approach guides an effective individualized treatment strategy that results in rapid sustained culture conversion.

Funder

European and Developing Countries Clinical Trials Partnership

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaa526/33517025/ciaa526.pdf

Reference14 articles.

1. Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care;Dookie;J Antimicrob Chemother,2018

2. Bedaquiline microheteroresistance after cessation of tuberculosis treatment;de Vos;N Engl J Med,2019

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. “As a patient I do not belong to the clinic, I belong to the community”: co-developing multi-level, person-centred tuberculosis stigma interventions in Cape Town, South Africa;BMC Global and Public Health;2024-08-15

2. “As a patient I do not belong to the clinic, I belong to the community.” Co-developing a multi-level, person-centred tuberculosis stigma intervention in Cape Town, South Africa;2024-02-08

3. Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment (SMARTT): a study protocol for a phase IV pragmatic randomized controlled patient management strategy trial;Trials;2022-10-08

4. Variants associated with Bedaquiline (BDQ) resistance identified in Rv0678 and efflux pump genes in Mycobacterium tuberculosis isolates from BDQ naïve TB patients in Pakistan;BMC Microbiology;2022-02-25